56. Behcet disease Clinical trials / Disease details


Clinical trials : 76 Drugs : 110 - (DrugBank : 32) / Drug target genes : 36 - Drug target pathways : 116

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-UMIN000012469
2013/12/0202/12/2013Comparison of Adalimumab and Steroid in Intestinal Behcet's diseaseComparison of Adalimumab and Steroid in Intestinal Behcet's disease - Castle Study Intestinal Behcet's diseaseSubcutaneous injection of adalumumab with 160mg at 0 week, 80mg at 2 weeks and 40mg every other week after at 4 weeks continuously.
Oral administration of prednisolone with 0.6mg/kg/day during from 1 to 2 weeks, and tapering off until 12 weeks with decreasing dosage 5mg/kg/week approximately
Castle Study GroupNULLRecruiting15years-oldNot applicableMale and Female50Not selectedJapan
2NCT00931957
(ClinicalTrials.gov)
October 201030/6/2009Etanercept: Single Blind Control Study in Ocular Manifestations of Behcet's DiseaseEtanercept: Single Blind Control Study in Ocular Manifestations of Behcet's DiseaseBehcet Syndrome;Uveal DiseaseDrug: Etanercept, Methotrexate, PrednisoloneTehran University of Medical SciencesWyeth is now a wholly owned subsidiary of PfizerRecruiting16 Years60 YearsBoth80N/AIran, Islamic Republic of